Journal of Surgery Concepts & Practice >

2024 , Vol. 29 >Issue 05: 405 - 408

DOI: https://doi.org/10.16139/j.1007-9610.2024.05.07

Consensus and guideline

The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

  • LU Yujie ,
  • ZHU Siji
Expand
  • Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2024-08-12

  Online published: 2025-01-23

Fold

Abstract

Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.

Key words： Breast cancer; Bone-modifying agent(BMA); Bisphosphonates(BP); Adjuvant treatment

Cite this article

LU Yujie , ZHU Siji . The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update[J]. Journal of Surgery Concepts & Practice, 2024 , 29(05) : 405 -408 . DOI: 10.16139/j.1007-9610.2024.05.07

References

[1] 中国医师协会肿瘤医师分会乳腺癌学组, 中国抗癌协会国际医疗交流分会. 骨改良药物安全性管理专家共识[J]. 中华肿瘤杂志, 2021, 43(6):622-628.
  Breast Cancer Group, Chinese Medical Doctor Association, International Medical Society, Chinese Anti-Cancer Association. Expert consensus on safety management of bone-modifying agents[J]. Chin J Oncol, 2021, 43(6):622-628.
[2] DHESY-THIND S, FLETCHER G G, BLANCHETTE P S, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:a cancer care ontario and American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2017, 35(18):2062-2081.
[3] GNANT M, PFEILER G, STEGER G G, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18):disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(3):339-351.
[4] COLEMAN R, FINKELSTEIN D M, BARRIOS C, et al. Adjuvant denosumab in early breast cancer (D-CARE):an international, multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1):60-72.
[5] GRALOW J R, BARLOW W E, PATERSON A H G, et al. Phase Ⅲ randomized trial of bisphosphonates as adjuvant therapy in breast cancer:S0307[J]. J Natl Cancer Inst, 2020, 112(7):698-707.
[6] FRIEDL T W P, FEHM T, MüLLER V, et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment:a phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(8):1149-1157.
[7] EISEN A, SOMERFIELD M R, ACCORDINO M K, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:ASCO-OH (CCO) guideline update[J]. J Clin Oncol, 2022, 40(7):787-800.
[8] Predict Breast:NHS PREDICT Tool[EB/OL]. [2024-08-12]. https://breast.predict.nhs.uk/.
[9] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer:meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015, 386(10001):1353-1361.
Options
Outlines

/

〈 〉